Review anchor
Serine/threonine-protein kinase TAO1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Serine/threonine-protein kinase TAO1
CHEMBL5261
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase TAO1 as ChEMBL target CHEMBL5261, mapped to UniProt Q7L7X3. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5261
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q7L7X3
Serine/threonine-protein kinase TAO1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Serine/threonine-protein kinase TAO1 matters
Serine/threonine-protein kinase TAO1 is reviewed as Serine/threonine-protein kinase TAO1 (UniProt Q7L7X3); the current evidence base includes 17 approved drugs, 1657 compounds, and 227 assays, with lead potency reaching pChEMBL 9.3.
Protein context
Serine/threonine-protein kinase TAO1
Serine/threonine-protein kinase TAO1 Sequence length is 1001 aa.
Review this target as Serine/threonine-protein kinase TAO1, mapped to UniProt Q7L7X3. Sequence length is 1001 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q7L7X3
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 17 approved drugs, 1657 compounds, and 227 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core Engine
17 approved
pChEMBL 9.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Serine/threonine-protein kinase TAO1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q7L7X3, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1657
Total Compounds
227
Total Assays
17
Approved Drugs
IC50: 218.0, KI: 891.0, KD: 336.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.3 | Kd | — |
|
|
No preferred name
CHEMBL388978
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL3544966
|
8.7 | Kd | — |
|
|
No preferred name
CHEMBL49120
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL1980995
|
8.0 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
Source Header